, Les patients avaient un âge médian de 30 ans (valeurs extrêmes : 8 -68 ans), p.87

, Leur suivi médian était de 100,5 mois (valeurs extrêmes : 1 -504 mois)

, Les patients présentaient un titre d'AAN médian de 1/1280 (valeurs extrêmes : 1/160 -1/1280)

, 8%) : il s'agissait d'Ac anti-ADN natif pour 66 patients (70,2%), des Ac anti-SSa et/ou SSb pour 37 patients (39,4%), des Ac anti-Sm pour 12 patients (12,8%), des Ac anti, On retrouvait d'autres auto-Ac chez 75 patients, vol.79

, 20 patients avaient un LA (22,0%), 15 patients avaient un Ac anti-bêta2GP1 (16,5%) et 23 avaient un aCL, vol.38

, Quarante-six patients (48,9%) présentaient une consommation du complément (C3 et/ou C4)

, 6%) avaient une anomalie à l'électrophorèse des protéines sériques dont 49 (56,3%) avaient une hypergammaglobulinémie polyclonale, Cinquante et un patients (sur les 87 testés, vol.58

, 2%) : il s'agissait d'arthralgies, concernant au moins 2 articulations, de rythme inflammatoire (dérouillage matinal ? 30 minutes) pour 67 d'entre eux (71,3%), d'arthrites (synovite impliquant au moins 2 articulations avec douleurs de rythme inflammatoire) dans 15 cas, La principale manifestation clinique du LES était rhumatologique, chez 82 patients, vol.87

, On retrouvait des lésions de lupus cutané aigu chez 43 patients (45,7%), de lupus cutané subaigu chez 6 patients (6,4%) et de lupus cutané chronique chez 10 patients (10,6%), La principale manifestation extra-rhumatologique était cutanéo-muqueuse et concernait 71 patients (75,5%)

G. Nocturne and X. Mariette, Advances in understanding the pathogenesis of primary Sjögren's syndrome, Nat Rev Rheumatol, vol.9, issue.9, pp.544-56, 2013.

G. Nocturne and X. Mariette, Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management, Br J Haematol, vol.168, issue.3, pp.317-344, 2015.

D. Cornec and L. Chiche, Is primary Sjögren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe, Ann Rheum Dis, vol.74, issue.3, p.25, 2015.

B. Qin, J. Wang, Z. Yang, M. Yang, N. Ma et al., Epidemiology of primary

, Sjögren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, vol.74, issue.11, pp.1983-1992, 2015.

M. Ramos-casals, R. Solans, J. Rosas, M. T. Camps, A. Gil et al.,

, Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore), vol.87, pp.210-219, 2008.

S. Stevens, Schirmer's test. Community Eye Health, vol.24, p.45, 2011.

C. A. Paschides, G. Kitsios, K. X. Karakostas, C. Psillas, and H. M. Moutsopoulos, Evaluation of tear break-up time, Schirmer's-I test and rose bengal staining as confirmatory tests for keratoconjunctivitis sicca, Clin Exp Rheumatol, vol.7, issue.2, pp.155-162, 1989.

A. Fauchais, B. Ouattara, G. Gondran, F. Lalloué, D. Petit et al., Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients, Rheumatol Oxf Engl, vol.49, issue.6, pp.1164-72, 2010.

M. Ramos-casals, J. Anaya, M. García-carrasco, J. Rosas, A. Bové et al., Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore), vol.83, pp.96-106, 2004.

L. Quartuccio, M. Isola, C. Baldini, R. Priori, E. Bartoloni et al., Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study, Scand J Rheumatol, vol.44, issue.1, pp.36-41, 2015.

D. M. Chisholm and D. K. Mason, Salivary gland disease, Br Med Bull, vol.31, issue.2, pp.156-164, 1975.

C. H. Shiboski, S. C. Shiboski, R. Seror, L. A. Criswell, M. Labetoulle et al., , 2016.

. Acr-eular, Classification Criteria for primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol Hoboken NJ, vol.69, pp.35-45, 2017.

C. J. Lessard, H. Li, I. Adrianto, J. A. Ice, A. Rasmussen et al., Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome, Nat Genet, vol.45, issue.11, pp.1284-92, 2013.

S. Tsunawaki, S. Nakamura, Y. Ohyama, M. Sasaki, A. Ikebe-hiroki et al., Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjögren's syndrome, J Rheumatol, vol.29, issue.9, pp.1884-96, 2002.

S. Katsiougiannis, R. Tenta, and F. N. Skopouli, Endoplasmic reticulum stress causes autophagy and apoptosis leading to cellular redistribution of the autoantigens Ro/Sjögren's syndrome-related antigen A (SSA) and La/SSB in salivary gland epithelial cells, Clin Exp Immunol, vol.181, issue.2, pp.244-52, 2015.

L. Kong, N. Ogawa, T. Nakabayashi, G. T. Liu, D. Souza et al., Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome, Arthritis Rheum, vol.40, issue.1, pp.87-97, 1997.

J. L. Pablos, P. E. Carreira, L. Morillas, G. Montalvo, C. Ballestin et al., Clonally expanded lymphocytes in the minor salivary glands of Sjögren's syndrome patients without lymphoproliferative disease, Arthritis Rheum, vol.37, issue.10, pp.1441-1445, 1994.

X. Mariette, S. Roux, J. Zhang, D. Bengoufa, F. Lavie et al., The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome, Ann Rheum Dis, vol.62, issue.2, pp.168-71, 2003.

C. Daridon, V. Devauchelle, P. Hutin, L. Berre, R. Martins-carvalho et al., Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum, vol.56, pp.1134-1178, 2007.

M. Kuwana, T. Okano, Y. Ogawa, J. Kaburaki, and Y. Kawakami, Autoantibodies to the aminoterminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjögren's syndrome, J Immunol Baltim Md, vol.167, issue.9, pp.5449-56, 1950.

J. Gottenberg, N. Cagnard, C. Lucchesi, F. Letourneur, S. Mistou et al., Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome, Proc Natl Acad Sci, vol.103, issue.8, pp.2770-2775, 2006.

J. C. Hall, L. Casciola-rosen, A. E. Berger, E. K. Kapsogeorgou, C. Cheadle et al., Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases, Proc Natl Acad Sci, vol.109, issue.43, pp.17609-17623, 2012.

X. Mariette, J. Gozlan, D. Clerc, M. Bisson, and F. Morinet, Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome, Am J Med, vol.90, issue.3, pp.286-94, 1991.

C. Croia, E. Astorri, W. Murray-brown, A. Willis, K. A. Brokstad et al., Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren's syndrome. Arthritis Rheumatol Hoboken NJ, vol.66, pp.2545-57, 2014.

K. Terada, S. Katamine, K. Eguchi, R. Moriuchi, M. Kita et al., Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome, Lancet Lond Engl, vol.344, issue.8930, pp.1116-1125, 1994.

P. Cacoub, C. Commarmond, D. Sadoun, and A. C. Desbois, Hepatitis C Virus Infection and Rheumatic Diseases: The Impact of Direct-Acting Antiviral Agents, Rheum Dis Clin North Am, vol.43, issue.1, pp.123-155, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01387968

A. A. Kruize, R. J. Hené, C. G. Kallenberg, O. P. Van-bijsterveld, A. Van-der-heide et al., Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial, Ann Rheum Dis, vol.52, issue.5, pp.360-364, 1993.

J. Gottenberg, P. Ravaud, X. Puéchal, L. Guern, V. Sibilia et al., Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial, JAMA, vol.312, issue.3, pp.249-58, 2014.

L. Arnaud, J. Fagot, A. Mathian, M. Paita, A. Fagot-campagna et al., Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study, Autoimmun Rev, vol.13, issue.11, pp.1082-1091, 2014.

R. Cervera, M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil et al., Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients, The European Working Party on Systemic Lupus Erythematosus

, Medicine (Baltimore), vol.72, pp.113-137, 1993.

S. Ribero, S. Sciascia, L. Borradori, and D. Lipsker, The Cutaneous Spectrum of Lupus Erythematosus, Clin Rev Allergy Immunol, vol.53, issue.3, pp.291-305, 2017.

T. Jacques, I. Sudo?-szopi?ska, N. Larkman, P. O'connor, and A. Cotten, Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, Sjögren's Syndrome, and Mixed Connective Tissue Disease, Semin Musculoskelet Radiol, 2018.

, Apr, vol.22, issue.2, pp.166-79

F. Aziz and K. Chaudhary, Lupus Nephritis: A Treatment Update, Curr Clin Pharmacol, vol.13, issue.1, pp.4-13, 2018.

J. J. Weening, D. 'agati, V. D. Schwartz, M. M. Seshan, S. V. Alpers et al., The classification of glomerulonephritis in systemic lupus erythematosus revisited, Kidney Int, vol.65, issue.2, pp.521-551, 2004.

, The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes, Arthritis Rheum, vol.42, issue.4, pp.599-608, 1999.

E. Badui, D. Garcia-rubi, E. Robles, J. Jimenez, L. Juan et al., Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients, Angiology, vol.36, issue.7, pp.431-472, 1985.

B. Memet and E. M. Ginzler, Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med, vol.28, pp.441-50, 2007.

N. Leuchten, A. Hoyer, R. Brinks, M. Schoels, M. Schneider et al., Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data, Arthritis Care Res, vol.70, issue.3, pp.428-466, 2018.

A. F. Kavanaugh and D. H. Solomon, Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests, Arthritis Care Res, vol.47, issue.5, pp.546-55, 2002.

M. Aringer, K. H. Costenbader, R. Brinks, D. Boumpas, D. Daikh et al., OP0020 Validation of new systemic lupus erythematosus classification criteria, Ann Rheum Dis, vol.77, issue.2, pp.60-60, 2018.

G. Thomas, J. Mancini, N. Jourde-chiche, G. Sarlon, Z. Amoura et al., Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-ofdeath analysis, Arthritis Rheumatol Hoboken NJ, vol.66, issue.9, pp.2503-2514, 2014.

C. Kuo, M. J. Grainge, A. M. Valdes, L. See, S. Luo et al., Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families, JAMA Intern Med, vol.175, issue.9, pp.1518-1544, 2015.

J. Leffler, A. A. Bengtsson, and A. M. Blom, The complement system in systemic lupus erythematosus: an update, Ann Rheum Dis, vol.73, issue.9, pp.1601-1607, 2014.

Y. J. Crow, Aicardi-Goutières syndrome, Handb Clin Neurol, vol.113, pp.1629-1664, 2013.

Y. Bilginer, A. Düzova, R. Topalo?lu, E. D. Batu, K. Boduro?lu et al., Three cases of spondyloenchondrodysplasia (SPENCD) with systemic lupus erythematosus: a case series and review of the literature, Lupus, vol.25, issue.7, pp.760-765, 2016.

M. Teruel and A. Me, The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned, J Autoimmun, vol.74, pp.161-75, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02044007

M. Barbhaiya and K. H. Costenbader, Environmental exposures and the development of systemic lupus erythematosus, Curr Opin Rheumatol, vol.28, issue.5, pp.497-505, 2016.

A. Mathian, L. Arnaud, and Z. Amoura,

, Rev Med Interne, vol.35, issue.8, pp.503-514, 2014.

A. Mathian, L. Arnaud, and Z. Amoura, Rev Prat, vol.61, issue.9, pp.1269-70, 2011.

L. M. Sur, E. Floca, D. G. Sur, M. C. Colceriu, G. Samasca et al., Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases, Lab Med, vol.49, issue.3, pp.62-73, 2018.

G. A. Mccarty, D. W. Valencia, M. J. Fritzler, and F. A. Barada, A unique antinuclear antibody staining only the mitotic-spindle apparatus, N Engl J Med, vol.305, issue.12, p.703, 1981.

B. K. Lydersen and D. E. Pettijohn, Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell, Cell, vol.22, issue.2, pp.489-99, 1980.

A. E. Radulescu and D. W. Cleveland, NuMA after 30 years: the matrix revisited, Trends Cell Biol, vol.20, issue.4, pp.214-236, 2010.

A. Tousson, C. Zeng, B. R. Brinkley, and M. M. Valdivia, Centrophilin: a novel mitotic spindle protein involved in microtubule nucleation, J Cell Biol, vol.112, issue.3, pp.427-467, 1991.

T. Maekawa, R. Leslie, and R. Kuriyama, Identification of a minus end-specific microtubuleassociated protein located at the mitotic poles in cultured mammalian cells, Eur J Cell Biol, vol.54, issue.2, pp.255-67, 1991.

M. A. Dionne, L. Howard, and D. A. Compton, NuMA is a component of an insoluble matrix at mitotic spindle poles, Cell Motil Cytoskeleton, vol.42, issue.3, pp.189-203, 1999.

C. Gueth-hallonet, K. Weber, and M. Osborn, NuMA: a bipartite nuclear location signal and other functional properties of the tail domain, Exp Cell Res, vol.225, issue.1, pp.207-225, 1996.

L. Haren and A. Merdes, Direct binding of NuMA to tubulin is mediated by a novel sequence motif in the tail domain that bundles and stabilizes microtubules, J Cell Sci, vol.115, pp.1815-1839, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00091096

Q. Du, L. Taylor, D. A. Compton, and I. G. Macara, LGN blocks the ability of NuMA to bind and stabilize microtubules. A mechanism for mitotic spindle assembly regulation, Curr Biol CB, vol.12, issue.22, pp.1928-1961, 2002.

M. E. Ludérus, J. L. Den-blaauwen, O. J. De-smit, D. A. Compton, and R. Van-driel, Binding of matrix attachment regions to lamin polymers involves single-stranded regions and the minor groove, Mol Cell Biol, vol.14, issue.9, pp.6297-305, 1994.

J. Harborth, S. M. Elbashir, K. Bechert, T. Tuschl, and K. Weber, Identification of essential genes in cultured mammalian cells using small interfering RNAs, J Cell Sci, vol.114, pp.4557-65, 2001.

A. D. Silk, A. J. Holland, and D. W. Cleveland, Requirements for NuMA in maintenance and establishment of mammalian spindle poles, J Cell Biol, vol.184, issue.5, pp.677-90, 2009.

A. Merdes, K. Ramyar, J. D. Vechio, and D. W. Cleveland, A complex of NuMA and cytoplasmic dynein is essential for mitotic spindle assembly, Cell, vol.87, issue.3, pp.447-58, 1996.
URL : https://hal.archives-ouvertes.fr/hal-00091112

T. Gaglio, A. Saredi, and D. A. Compton, NuMA is required for the organization of microtubules into aster-like mitotic arrays, J Cell Biol, vol.131, issue.3, pp.693-708, 1995.

L. E. Andrade, E. K. Chan, C. L. Peebles, and E. M. Tan, Two major autoantigen-antibody systems of the mitotic spindle apparatus, Arthritis Rheum, vol.39, issue.10, pp.1643-53, 1996.

C. Zeng, NuMA: a nuclear protein involved in mitotic centrosome function, Microsc Res Tech, vol.49, issue.5, pp.467-77, 2000.

D. A. Compton and D. W. Cleveland, NuMA is required for the proper completion of mitosis, J Cell Biol, vol.120, issue.4, pp.947-57, 1993.

C. H. Yang, E. J. Lambie, and M. Snyder, NuMA: an unusually long coiled-coil related protein in the mammalian nucleus, J Cell Biol, vol.116, issue.6, pp.1303-1320, 1992.

C. M. Whitehead and J. B. Rattner, Expanding the role of HsEg5 within the mitotic and postmitotic phases of the cell cycle, J Cell Sci, vol.111, pp.2551-61, 1998.

A. Blangy, H. A. Lane, P. Hérin, M. Harper, M. Kress et al., Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo, Cell, vol.83, issue.7, pp.1159-69, 1995.

M. J. Fritzler, J. D. Pauls, T. D. Kinsella, and T. J. Bowen, Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors, Clin Immunol Immunopathol, vol.36, issue.1, pp.120-128, 1985.

C. M. Price, G. A. Mccarty, and D. E. Pettijohn, NuMA protein is a human autoantigen, Arthritis Rheum, vol.27, issue.7, pp.774-783, 1984.

R. Szalat, P. Ghillani-dalbin, M. Jallouli, Z. Amoura, L. Musset et al., Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: Clinical and immunological features: A propos of 40 new cases and review of the literature, Autoimmun Rev, 2010.

B. Bonaci-nikolic, S. Andrejevic, M. Bukilica, I. Urosevic, and M. Nikolic, Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance, J Clin Immunol, vol.26, issue.5, pp.438-484, 2006.

L. Mozo, C. Gutiérrez, and J. Gómez, Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies, J Clin Immunol, vol.28, issue.4, pp.285-90, 2008.

Y. Sherer, A. Gorstein, M. J. Fritzler, and Y. Shoenfeld, Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients, Semin Arthritis Rheum, vol.34, issue.2, pp.501-538, 2004.

P. Auer-grumbach and M. Stangl, Autoantibodies to nuclear mitotic apparatus in a patient with vitiligo and autoimmune thyroiditis, Dermatol Basel Switz, vol.186, issue.3, pp.229-260, 1993.

K. Lind, M. Høier-madsen, and A. Wiik, Autoantibodies to the mitotic spindle apparatus in Mycoplasma pneumoniae disease, Infect Immun, vol.56, issue.3, pp.714-719, 1988.

L. Tan, Y. Zhang, Y. Jiang, H. Li, J. Chen et al., The clinical significance of antimitotic spindle apparatus antibody (MSA) and anti-centromere antibody (ACA) detected in patients with small cell lung cancer (SCLC), Am J Clin Exp Immunol, vol.6, issue.2, pp.21-27, 2017.

P. Grypiotis, A. Ruffatti, M. Tonello, C. Winzler, C. Radu et al., Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases

V. Limaye, P. Roberts-thomson, D. Gillis, and K. Pile, The clinical associations of mitotic spindle autoantibodies in a South Australian cohort, Aust N Z J Med, 1999.

J. F. Betancur, A. Londoño, V. E. Estrada, S. L. Puerta, S. M. Osorno et al., Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations, Medicine (Baltimore), vol.97, issue.34, p.11727, 2018.

Q. Xi, Y. Wu, L. Li, B. Cai, J. Zhang et al., Anti-Mitotic Spindle Apparatus Antoantibodies: Prevalence and Disease Association in Chinese Population, J Clin Lab Anal, vol.30, issue.5, pp.702-710, 2016.

G. A. Mccarty, D. W. Valencia, and M. J. Fritzler, Antibody to the mitotic spindle apparatus: immunologic characteristics and cytologic studies, J Rheumatol, vol.11, issue.2, pp.213-221, 1984.

C. M. Whitehead, R. J. Winkfein, M. J. Fritzler, and J. B. Rattner, The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus, Arthritis Rheum, 1996.

P. Auer-grumbach and B. Achleitner, Epidemiology and clinical associations of NuMA (nuclear mitotic apparatus protein) autoantibodies, J Rheumatol, vol.21, issue.9, pp.1779-81, 1994.

F. A. Houssiau, C. Vasconcelos, D. Cruz, D. Sebastiani, G. D. De-ramon-garrido et al., The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide, Ann Rheum Dis, vol.69, issue.1, pp.61-65, 2010.

N. Agmon-levin, J. Damoiseaux, C. Kallenberg, U. Sack, T. Witte et al., International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies, Ann Rheum Dis, vol.73, issue.1, pp.17-23, 2014.

Q. Sun and H. Schatten, Role of NuMA in vertebrate cells: review of an intriguing multifunctional protein, Front Biosci J Virtual Libr, vol.11, pp.1137-1183, 2006.

K. Gehmlich, L. Haren, and A. Merdes, Cyclin B degradation leads to NuMA release from dynein/dynactin and from spindle poles, EMBO Rep, vol.5, issue.1, pp.97-103, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00091085

M. B. Gordon, L. Howard, and D. A. Compton, Chromosome movement in mitosis requires microtubule anchorage at spindle poles, J Cell Biol, vol.152, issue.3, pp.425-459, 2001.

M. Kallajoki, K. Weber, and M. Osborn, A 210 kDa nuclear matrix protein is a functional part of the mitotic spindle; a microinjection study using SPN monoclonal antibodies, EMBO J, vol.10, issue.11, pp.3351-62, 1991.

M. Kallajoki, J. Harborth, K. Weber, and M. Osborn, Microinjection of a monoclonal antibody against SPN antigen, now identified by peptide sequences as the NuMA protein, induces micronuclei in PtK2 cells, J Cell Sci, vol.104, pp.139-50, 1993.

A. A. Levesque, L. Howard, M. B. Gordon, and D. A. Compton, A functional relationship between NuMA and kid is involved in both spindle organization and chromosome alignment in vertebrate cells, Mol Biol Cell, vol.14, issue.9, pp.3541-52, 2003.

C. H. Yang and M. Snyder, The nuclear-mitotic apparatus protein is important in the establishment and maintenance of the bipolar mitotic spindle apparatus, Mol Biol Cell, vol.3, issue.11, pp.1259-67, 1992.

Y. Berda-haddad, S. Robert, P. Salers, L. Zekraoui, C. Farnarier et al., Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1?

, Proc Natl Acad Sci U S A, vol.108, issue.51, pp.20684-20693, 2011.

T. Lechler and E. Fuchs, Asymmetric cell divisions promote stratification and differentiation of mammalian skin, Nature, vol.437, issue.7056, pp.275-80, 2005.

K. H. Siller and C. Q. Doe, Spindle orientation during asymmetric cell division, Nat Cell Biol, vol.11, issue.4, pp.365-74, 2009.

Q. Du, P. T. Stukenberg, and I. G. Macara, A mammalian Partner of inscuteable binds NuMA and regulates mitotic spindle organization, Nat Cell Biol, vol.3, issue.12, pp.1069-75, 2001.

A. Merdes and D. W. Cleveland, The role of NuMA in the interphase nucleus, J Cell Sci, vol.111, pp.71-80, 1998.
URL : https://hal.archives-ouvertes.fr/hal-00091109

X. Fant, A. Merdes, and L. Haren, Cell and molecular biology of spindle poles and NuMA, Int Rev Cytol, vol.238, pp.1-57, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00091141

P. Taimen, M. Viljamaa, and M. Kallajoki, Preferential expression of NuMA in the nuclei of proliferating cells, Exp Cell Res, vol.256, issue.1, pp.140-149, 2000.

M. Daynac and C. K. Petritsch, Regulation of Asymmetric Cell Division in Mammalian Neural Stem and Cancer Precursor Cells, Results Probl Cell Differ, vol.61, pp.375-99, 2017.

C. Q. Doe, Asymmetric cell division and neurogenesis, Curr Opin Genet Dev, vol.6, issue.5, pp.562-568, 1996.

F. Yu, C. T. Kuo, and Y. N. Jan, Drosophila neuroblast asymmetric cell division: recent advances and implications for stem cell biology, Neuron, vol.51, issue.1, pp.13-20, 2006.

Q. Shen, W. Zhong, Y. N. Jan, and S. Temple, Asymmetric Numb distribution is critical for asymmetric cell division of mouse cerebral cortical stem cells and neuroblasts, Dev Camb Engl, vol.129, issue.20, pp.4843-53, 2002.

A. Marciniak-czochra, T. Stiehl, A. D. Ho, W. Jäger, and W. Wagner, Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation, Stem Cells Dev, vol.18, issue.3, pp.377-85, 2009.

B. Giebel, Cell polarity and asymmetric cell division within human hematopoietic stem and progenitor cells, Cells Tissues Organs, vol.188, issue.1-2, pp.116-142, 2008.

J. Beckmann, S. Scheitza, P. Wernet, J. C. Fischer, and B. Giebel, Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins, Blood, vol.109, issue.12, pp.5494-501, 2007.

D. T. Bergstralh and D. St-johnston, Spindle orientation: what if it goes wrong? Semin Cell Dev Biol, vol.34, pp.140-145, 2014.

L. Ferhat, C. Cook, R. Kuriyama, and P. W. Baas, The nuclear/mitotic apparatus protein NuMA is a component of the somatodendritic microtubule arrays of the neuron, J Neurocytol, vol.27, issue.12, pp.887-99, 1998.

T. Both, V. Dalm, P. M. Van-hagen, and P. Van-daele, Reviewing primary Sjögren's syndrome: beyond the dryness -From pathophysiology to diagnosis and treatment, Int J Med Sci, vol.14, issue.3, pp.191-200, 2017.

M. Rischmueller, J. Tieu, and S. Lester, Primary Sjögren's syndrome, Best Pract Res Clin Rheumatol, vol.30, issue.1, pp.189-220, 2016.

J. Ioannidis, V. A. Vassiliou, and H. M. Moutsopoulos, Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum, vol.46, pp.741-748, 2002.

N. Rothfield, R. D. Sontheimer, and M. Bernstein, Lupus erythematosus: systemic and cutaneous manifestations, Clin Dermatol, vol.24, issue.5, pp.348-62, 2006.

J. Font, R. Cervera, M. Ramos-casals, M. Garc?á-carrasco, J. Sent?? et al., Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center, Semin Arthritis Rheum, vol.33, issue.4, pp.217-247, 2004.

, Résumé Les anticorps (Ac) anti-NuMA représentent des auto-Ac identifiés sur une fluorescence particulière sur les cellules en mitose lors de la recherche d'Ac antinucléaires

, Soixante-six (73,3%) d'entre eux avaient une fluorescence anti-NuMA1 et 24 patients (26,7%) avaient une fluorescence anti-NuMA2. Parmi ces 90 patients, 70 (77,7%) souffraient d'une maladie systémique et 61 (67,8%) avaient une maladie auto-immune : syndrome de Sjögren primitif, Sur une cohorte rétrospective de 90 patients porteurs d'Ac anti-NuMA, nous avons identifié que la prévalence de ces Ac était de 0,36%

, Quatre patients (4,4%) présentaient une pathologie cancéreuse et quatre patients (4,4%) avaient une maladie infectieuse. Douze patients (13,3%) souffraient de maladies diverses

, Lorsque l'on comparait les caractéristiques entre les patients porteurs d'Ac anti-NuMA1 par rapport à ceux porteurs d'Ac anti-NuMA2, on notait un titre d'Ac antinucléaires plus élevé (1/789,7 versus 1/457,5), une association plus fréquente à d'autres auto-Ac (26,2% versus 15,9%) et une association plus fréquente aux maladies auto-immunes (72,4%, versus 60,2%) chez les patients avec Ac anti-NuMA1. Leur comparaison a permis de montrer que les patients avec des maladies auto-immunes et des anti-NuMA étaient plus jeunes (52,1 ans versus 54,7 ans), davantage des femmes (85,3% versus 66,3%) et avaient un titre d'Ac antinucléaires plus important (1/1192,3 versus 1/595,5), une association à d'autres auto-Ac, En réalisant une revue exhaustive de la littérature, nous avons identifié 12 études rapportant les caractéristiques de patients porteurs d'Ac anti-NuMA, qui présentaient en moyenne les mêmes caractéristiques que les patients de notre cohorte, vol.29

L. Ssp, étant les deux maladies auto-immunes les plus fréquemment retrouvées chez les patients porteurs d'Ac anti-NuMA, nous avons décidé d'étudier l'impact de la présence d'Ac anti-NuMA sur le phénotype de ces patients par rapport à ceux qui ne possèdent pas de tels Ac

, Nous avons observé que les patients avec Ac anti-NuMA étaient moins sujets au syndrome sec ophtalmique (70% versus 89,1%, p = 0,031) ou à des complications du syndrome sec (15% versus 39,4%, p = 0,045), moins porteurs d'Ac anti-ENA (40% versus 68,6%, p = 0,022), notamment d'Ac anti-SSa et/ou SSb (40% versus 66,4%, p = 0,027), et avaient reçu moins de traitements (nombre médian de lignes de traitement : 1 versus 2, p < 0,01), 30% versus 24,8%), neurologiques du SSp (15% versus 5,8%), et moins de syndrome sec buccal (80% versus 86,1%), de manifestations rhumatologiques

, 019) et avaient moins d'auto-Ac (50,0% versus 85,0%, p < 0,01) en particulier moins d'Ac anti-ADN natifs (42,9% versus 75,0%, p = 0,025) et d'anti-SSa/SSb (7,1% versus 45,0%, p < 0,01), moins de consommation du complément (21,4% versus 53,8%, p = 0,040), moins d'hypergammaglobulinémie polyclonale (20,0% versus 61,0%, p = 0,019) et plus de thrombopénie (35,7% versus 12,5%, p = 0,044) que les patients sans Ac anti-NuMA. Les patients avec anti-NuMA avaient reçu moins de traitement par antipaludéen de synthèse, Nous avons alors comparé 14 patients avec un LES et des Ac anti-NuMA et 80 patients atteints de LES sans anti-NuMA. Nous avons pu noter que les patients avec anti-NuMA ne présentaient pas de glomérulonéphrite lupique (0% versus 28, vol.8, p.0

. Ainsi, en évidence que les patients présentant un Ac anti-NuMA avaient un profil phénotypique et évolutif particulier qui pourrait être lié au rôle particulier de ces auto

. Serment-d&apos;hippocrate,

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité